Ultrasonographic Tissue Thickness After Complex Decongestive Therapy in Lower-Limb Lymphedema
Effect of Complex Decongestive Therapy on Subcutaneous Tissue Thickness in Lower-Limb Lymphedema: A Prospective Ultrasonographic Study With Contralateral Internal Control
This prospective single-center study evaluated whether 4 weeks of phase-1 complex decongestive therapy (manual lymphatic drainage, multilayer short-stretch bandaging, decongestive exercise, and skin care) changes dermal and subcutaneous tissue thickness measured by high-frequency ultrasonography in adults with unilateral International Society of Lymphology stage 1-2 lower-limb lymphedema. Measurements were made at suprapatellar and infrapatellar sites of both limbs before and after treatment; the unaffected limb served as an internal control and body weight was recorded to distinguish local tissue change from systemic weight change.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Participants received a standardized 20-session (5 days/week, 4 weeks) intensive-phase complex decongestive therapy program delivered by an experienced physiotherapist. Ultrasonographic measurements were performed with a 10-14 MHz linear probe using a minimal-compression technique after 15 minutes of supine rest, at the same time of day, by an assessor blinded to baseline values; intra-rater reliability (intraclass correlation coefficient 0.92) was established in 10 patients. The sample size (n = 34; Cohen's d = 0.5, power 80%, alpha 0.05; 40 recruited) was calculated with G*Power. Paired comparisons (paired t-test or Wilcoxon signed-rank test), 95% confidence intervals, Cohen's d, and Pearson correlation of treatment response with age, body mass index, and disease duration were planned.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Kontakte und Standorte
Studienorte
-
-
-
Kayseri, Türkei (türkiye), 38080
- Kayseri City Training and Research Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Adults presenting to the Physical Medicine and Rehabilitation outpatient clinic of Kayseri City Hospital with unilateral lower-limb lymphedema and an indication for intensive-phase complex decongestive therapy.
Beschreibung
Inclusion Criteria:
- Age 18 years or older
- Unilateral lower-limb lymphedema, International Society of Lymphology stage 1 or 2 (2020 consensus)
- Diagnosis supported by lymphoscintigraphy
- Indication for intensive-phase complex decongestive therapy
- No previous full course of complex decongestive therapy on the affected limb
- Written informed consent
Exclusion Criteria:
- Active cellulitis or erysipelas at the measurement sites
- Active, recurrent, or metastatic malignancy
- Decompensated heart failure or history of deep vein thrombosis
- Bilateral lymphedema
- Cognitive impairment preventing adherence to treatment
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Lower-limb lymphedema, complex decongestive therapy
Adults with unilateral ISL stage 1-2 lower-limb lymphedema who received 4 weeks (20 sessions) of phase-1 complex decongestive therapy as standard care. Dermal and subcutaneous tissue thickness were measured by high-frequency ultrasonography at suprapatellar and infrapatellar sites of both limbs before and after treatment; the unaffected limb served as an internal control. |
Phase-1 (intensive) complex decongestive therapy delivered 5 days per week for 4 weeks (20 sessions) by an experienced physiotherapist: Vodder-technique manual lymphatic drainage (30-45 min), multilayer short-stretch compression bandaging from the toes to the proximal thigh, decongestive range-of-motion exercise performed with bandages in place, and daily skin care with a pH 5.5 moisturizer.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in subcutaneous tissue thickness of the affected limb at the suprapatellar site
Zeitfenster: Baseline and end of week 4 (after 20 sessions of complex decongestive therapy)
|
Subcutaneous tissue thickness (dermis-subcutis interface to deep fascia) measured in millimeters by B-mode ultrasonography with a 10-14 MHz linear probe using a minimal-compression technique. |
Baseline and end of week 4 (after 20 sessions of complex decongestive therapy)
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in subcutaneous tissue thickness of the affected limb at the infrapatellar site
Zeitfenster: Baseline and end of week 4
|
Subcutaneous tissue thickness in millimeters measured by B-mode ultrasonography (10-14 MHz linear probe, minimal-compression technique). |
Baseline and end of week 4
|
|
Change in dermal thickness of the affected limb at the suprapatellar and infrapatellar sites
Zeitfenster: Baseline and end of week 4
|
Dermal thickness (skin surface to dermis-subcutis interface) in millimeters measured by B-mode ultrasonography. |
Baseline and end of week 4
|
|
Change in subcutaneous tissue thickness of the unaffected (control) limb
Zeitfenster: Baseline and end of week 4
|
Subcutaneous tissue thickness of the contralateral unaffected limb at the suprapatellar and infrapatellar sites, in millimeters, measured by B-mode ultrasonography; serves as an internal control. |
Baseline and end of week 4
|
|
Change in body weight
Zeitfenster: Baseline and end of week 4
|
Body weight in kilograms measured on the same calibrated scale, recorded to distinguish local tissue change from systemic weight change. |
Baseline and end of week 4
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Correlation of subcutaneous thickness change with disease duration, age, and body mass index
Zeitfenster: Baseline and end of week 4
|
Pearson correlation coefficients between the change in suprapatellar subcutaneous thickness of the affected limb and disease duration (months), age (years), and body mass index (kg/m2). |
Baseline and end of week 4
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Abdullah Goktug Yazar, MD, Kayseri City Hospital
- Studienstuhl: Ayse Guc, MD, Kayseri City Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 2025-491
- 491 (Andere Kennung: Kayseri City Hospital Clinical Research Ethics Committee)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .